Option chain shows key data for Theriva Biologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Theriva Biologics.

Theriva Biologics (AMEX:TOVX) Stock, Option Chain

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Wall Street

Equities

News

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

ETFs

AVGR

CREV

NEUE

NVDA

TIVC

TOVX

TSLA

U.S. stock futures advanced on Tuesday, head of a shortened trading session owning to Christmas-eve. The stock market will shut at 1 p.m. ET.

US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Movers

AMPG

BIPC

CHEK

FDSB

HSDT

KORE

LAES

LIND

NCRA

NVNI

RELI

SLGL

TLRY

Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket

Essential medicines

Theriva stock is trading higher after the company announced it was selected as a finalist for Merck&#39;s KGaA&#39;s EMEA Advance Biotech Grant.

What&#39;s Going On With Theriva Biologics Stock Friday?

Theriva Biologics Inc

Press Releases

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

General

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Health Care

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

Earnings

Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Azitra

Capstone Holding

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Ensysce Biosciences

Galecto

Genprex

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Organovo Holdings

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

Maxim Group

Screenshot 2024-08-23 at 5.34.20 PM

Biotech

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Comments

Theriva Biologics

Theriva Biologics (TOVX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga